Satio and Nanowear have entered a partnership agreement aimed at progressing home-based diagnostic and therapeutic care that ...

Satio and Nanowear today announced that they partnered to advance patient-friendly, home-based diagnostic and therapeutic ...

DexCom (NasdaqGS:DXCM) recently experienced a 14% price increase over the past week. This uptick coincides with the company's announcement of FDA clearance for the Dexcom G7 Continuous Glucose ...

For Investigational Purposes, Nanowear’s app, platform, and server will transmit Dexcom G7 CGM data, offering first-in-the-world, home-based, self-administered, continuous cardiometabolic ...

Nanowear, a leader in home-based cardiometabolic digital diagnostics announced that SimpleSense™, a nanotechnology-enabled wearable, mobile and software diagnostics platform, will ingest glucose ...

For Investigational Purposes, Nanowear’s app, platform, and server will transmit Dexcom G7 CGM data, offering first-in-the-world, home-based, self-administered, continuous cardiometabolic assessments ...